Kavain Analogues As Potential Analgesic Agents

Total Page:16

File Type:pdf, Size:1020Kb

Kavain Analogues As Potential Analgesic Agents Pharmacological Reports Copyright © 2012 2012, 64, 14191426 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Kavainanaloguesaspotentialanalgesicagents ElaineC.Kormann1,PatriciadeAguiarAmaral2,MicheleDavid3, VeraL.Eifler-Lima4,ValdirCechinelFilho1,FátimadeCamposBuzzi1 1 Chemical-PharmaceuticalInvestigationsCenter(NIQFAR)/CCS,UniversityofItajaíValey(UNIVALI),Itajaí/SC, Brazil 2 LaboratoryofMedicinalPlants(LaPlaM),UniversityoftheExtremeSouthofSantaCatarina(UNESC), Criciúma/SC,Brazil 3 LaboratoryofChemistryTherapeutic(UPRES4090),UniversityofRennes1,Rennes,France 4 LaboratoryofMedicinalOrganicSynthesis(LaSOM),FacultyofPharmacy,FederalUniversityofRioGrande doSul(UFRGS),PortoAlegre/RS,Brazil Correspondence: FátimadeCamposBuzzi,e-mail: [email protected]; VeraL.Eifler-Lima, e-mail: [email protected] Abstract: Background: Kavalactones are pharmacologically active compounds present in preparations of the root trunk of Piper methysticum Forst, known as kava. This work describes the analgesic activity of some synthesized analogues of synthetic kavain, which is the maincomponentofkava. Methods: The essays were initially performed against the writhing test in mice, and the most promising compound was analyzed us- ing other classical models of nociception, including formalin-, capsaicin-, glutamate-induced nociception, the hot plate test, and measurementofmotorperformance. Results: The results indicated that compound 6-(4-fluorophenyl)-4-methoxy-5,6-dihydropyran-2-one (2d) exerts potent and dose- dependent analgesic activity, inhibiting abdominal constrictions caused by acetic acid in mice, and being more active than some ref- erence drugs. It also presented activity in the other models of pain, with the exception of the hot plate test and the measurement of motorperformance. Conclusions: Although compound 2d exerts antinociceptive activity, the mechanism of action remains uncertain, but it does not in- volve the opioid system and does not appear to be associated with non-specific effects such as changes in locomotor activity or motor coordination. Keywords: kavain,lactones,enolethers, d-valerolactones,antinociceptiveactivity Introduction ethylene-a-pyrone skeleton. They are typically 4- methoxy-2-pyrones with a phenyl or styryl substituent at the 6-position [2]. The commercial extracts consist The active constituents for the therapeutic actions of of a mixture of more than 18 different a-pyrones, col- Piper methysticum (kava) extract consist of a group of lectively known as kavapyrones, or kavalactones. The structurally related lipophilic derivatives with an aryl- major constituents are (+)-kavain (1.8%), (+)-methy- Pharmacological Reports, 2012, 64, 14191426 1419 sticin (1.2%), desmethoxyangonin (1.0%), (+)-di- tions. Since some suffering might result from the ex- hydrokavain (0.6%), (+)-dihydromesthysticin (0.5%), periments, the International Association for the Study tetrahydroxyangonin. Minor constituents included of Pain (IASP) Committee for Research and Ethical other kavalactones, chalcones and essential oils [9]. Issues Guidelines [28] were followed, and the experi- Pharmacological studies have revealed that these sub- ments were approved by the Animal Ethics Commit- stances are responsible for the analgesic [1], sedative tee of UNIVALI (protocol no. 609/2007 UNIVALI), [10, 22], anticonvulsive [16] and spasmolytic proper- and all the experiments were conducted according to ties [23] of kava. Four lactones from kava (kavain, di- the principles of the Brazilian College of Animal Ex- hydrokavain, methysticin, and dihydromethysticin) perimentation(COBEA). have been found to possess significant analgesic ef- fects in animal studies, probably by non-opiate path- Chemistry ways [18]. Kavain (1) appears to be the most effective in surface anesthesia, comparable to cocaine in its The solvents were distilled prior to use, following the strength and duration of action [21]. It was selected as standard procedures, and reactions were performed the prototype because of its yield in the plant extract, under nitrogen or argon atmosphere. Silica gel 60 F254 and because it presented analgesic activity in previous plates were used to monitor the synthetic transforma- studies [1]. In this work, we have synthesized kavain tions, with visualization under UV light, 2% KMnO4 (1) and nine analogues, according to a previous report or sulfuric anisaldehyde 2% solutions. Chromato- of an aldolization-lactonization process [3], and graphic purifications were carried out using 70–230 evaluated these compounds in models of pain in mice. mesh silica gel. Melting points were determined on a System Kofler type WME apparatus, and were un- corrected. Infrared (FT-IR) spectra were recorded with a Perkin Elmer 1600 spectrometer. Nuclear mag- netic resonance spectra (1H NMR and 13C NMR) were MaterialsandMethods recorded on a Bruker AC-200F spectrometer and per- formed at 300 MHz and 75 MHz, respectively. d Drugs Chemical shifts ( values) are given in parts per mil- lion downfield from tetramethylsilane as the internal The following drugs and reagents were used: acetyl- standard. Mass spectral analyses were performed at salicylic acid (ASA), metamizole (MET), capsaicin the Centre Régional de Mesures Physiques de l’Ouest and glutamate (Sigma Chemical Co., St. Louis, USA); (CRMPO) in Rennes (France). All the compounds formalin, acetic acid (Vetec, Rio de Janeiro, Brazil) (Fig. 1) have already being described by some of the and morphine (Dimorf®), kindly provided by authorsinreference[3]. Cristália (Itapira, São Paulo, Brazil). The compounds studied, as well as the reference drugs, were dissolved in Tween 80 (Merck, AG, Darmstadt, Germany), with the exception of the capsaicin, which was dissolved in ethanol, plus 0.9% of NaCl solution. The final con- centration of Tween and ethanol did not exceed 5% anddidnotcauseanyeffect“perse”. Animals The animals used were Swiss male mice (25–30 g), obtained from the University of Vale do Itajaí (Itajaí, Brazil). They were kept in a temperature-controlled environment (23 ± 2°C) with a 12 h light-dark cycle. Food and water were freely available. The allocation of animals into different groups was randomized, and the experiments were carried out under blind condi- Fig.1. Structureofkavainandthecompoundsevaluated 1420 Pharmacological Reports, 2012, 64, 14191426 Analgesiceffectsofkavainanalogues Elaine C. Kormann et al. PHARMACOLOGY placed in a glass cylinder of 20 cm in diameter, and the time spent licking the injected paw (second phase Abdominalconstrictionresponsecausedby offormalintest)wasdetermined. injectionofaceticacid Capsaicin-inducedpain Abdominal constrictions induced by intraperitoneal (ip) injection of acetic acid (0.6%), consisting of The procedure used was similar to that described pre- a contraction of the abdominal muscle together with viously [25]. Animals were placed individually in a stretching of the hind limbs, were counted according transparent glass cylinders. Following the adaptation to the previously described procedures [10]. The ani- period, 20 µl of capsaicin (1.6 µg/paw) was injected mals were pretreated with 10 mg/kg of all analogues under the skin of the plantar surface of the right hind from kavain (1) or standard drugs via the intraperito- paw, using a microsyringe. The animals were ob- neal route, 30 min before acetic acid injection. The served individually for 5 min following capsaicin in- control animals received a similar volume of vehicle jection. The amount of time spent licking the injected (Tween 80 and 0.9% NaCl). For compounds 1, 2a, 2b, paw was timed with a chronometer and was consid- 2d and 3c the abdominal constriction response was ered as indicative of nociception. The animals were ip analyzed, following pretreatment via the ip route in treated with compound 2d at 1, 3 and 10 mg/kg or sa- three doses (1 to 30 mg/kg) or the standard drugs, but line 1 h before administration of capsaicin. The con- in higher doses (10 to 60 mg/kg) for evaluation of trol animals received a similar volume of 0.9 % NaCl ID50. The enol ether 2d (6-(4-fluorophenyl)-4-methoxy- (10ml/kg, ip). 5,6-dihydropyran-2-one), which was the most active of the compounds tested, was also analyzed orally at Glutamate-inducednociception 100 mg/kg. After the challenge, pairs of mice were placed in separate boxes and the number of abdominal The animals were treated with the compound 2d ip (1, constrictions was cumulatively counted over a period 30 and 60 mg/kg) 30 min before capsaicin injection, of 20 min. Antinociception was expressed as the re- respectively. A volume of 20 µl of glutamate solution duction in the number of abdominal constrictions be- (30 µmol/ paw), made up in phosphate buffered saline tween the control animals and the mice pretreated (PBS), was injected intraplantarly under the surface withcompoundsorstandarddrugs. of the right hind paw as described previously [4]. Af- ter injection with glutamate, the animals were indi- Formalin-inducedpain vidually placed in glass cylinders of 20 cm in diame- ter and observed from 0 to 15 min. The time spent The procedure was similar to that described previ- licking and biting the injected paw was timed with ously [17, 25]. The observation chamber was a glass achronometerandconsideredasindicativeofpain. cylinder of 20 cm in diameter, with a mirror at a 45° angle to allow clear observation of the animal’s paws. Hot-platetest For the formalin-induced pain 20 µl of 2.5% formalin (0.92% formaldehyde) was injected under the surface The hot-plate test
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 Mccleary Et Al
    US 200301 05159A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 McCleary et al. (43) Pub. Date: Jun. 5, 2003 (54) KAVALACTONE COMPOSITIONS AND Publication Classification METHODS OF USE (51) Int. Cl." ....................... A61K 31/35; A61K 31/366; (76) Inventors: Joel McCleary, The Plains, VA (US); A61K 35/78; A61K 31/16 Peter S. Staats, Towson, MD (US) (52) U.S. Cl. ........................... 514/460; 514/625; 424/760 Correspondence Address: FISH & RICHARDSON PC 225 FRANKLIN ST BOSTON, MA 02110 (US) (57) ABSTRACT (21) Appl. No.: 10/214,624 (22) Filed: Aug. 8, 2002 This invention relates tO kavalactone-containing composi tions, and more particularly to compositions having com Related U.S. Application Data pounds derived from kavalactones and from capsaicinoids. The compositions are useful in modulating pain, and thus (60) Provisional application No. 60/311,437, filed on Aug. can be used to mediate, or eliminate, Sensations of pain, 10, 2001. thereby providing pain relief and reduction. US 2003/0105159 A1 Jun. 5, 2003 KAVALACTONE COMPOSITIONS AND METHODS 0006. In one embodiment, the invention relates to an OF USE analgesic topical composition having: (a) a kavalactone; (b) capsaicinoid or Synthetic derivatives thereof; and (c) a CROSS-REFERENCE TO RELATED pharmaceutically acceptable carrier; wherein the weight APPLICATIONS ratio of(a):(b) is from 5000:1 to 1:2 (e.g., 800:1 to 1:1; 500:1 to 5:1). In other aspects, the composition includes an effec 0001. This application claims benefit of U.S. application tive amount of kavalactones, active kavalactones, or capsai Ser.
    [Show full text]
  • Kava (Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue Against Ischemic Damage in Rodents
    5 Refs: Arletti R et al, Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology 143(1), 15-19, 1999. Berger F, Handbuch der drogenkunde . Vol 2, Maudrich, Wien, 1950. Martinez M, Les plantas medicinales de Mexico . Cuarta Edicion Botas Mexico , p119, 1959. Tyler VE et al, Pharmacognosy , 9 th edition, Lea & Febiger, Philadelphia, 1988. KAVA ( Piper methysticum ) - A REVIEW The Kava plant (Piper methysticum) is a robust, well-branching and erect perennial shrub belonging to the pepper family (Piperaceae). The botanical origin remains unknown, although it is likely that early Polynesian explorers brought the plant with them from island to island. Numerous varieties of Kava exist, and today it is widely cultivated in several Pacific Island countries both for local use as well as the rapidly growing demand for pharmaceutical preparations. The dried rhizomes (roots) are normally used. The first description to the western world of the ceremonial use of an intoxicating beverage prepared from Kava was made by Captain James Cook following his Pacific voyage in 1768. The drink, prepared as an infusion in an elaborate manner after first chewing the root, is consumed on formal occasions or meetings of village elders and chiefs, as well as in reconciling with enemies and on a more social basis. It remains an important social custom in many Pacific Island countries today. Most of the islands of the Pacific possessed Kava prior to European contact, particularly those encompassed by Polynesia, Melanesia and Micronesia. After drinking the Kava beverage a pleasantly relaxed and sociable state develops, after which a deep and restful sleep occurs.
    [Show full text]
  • Alternative Treatments for Depression and Anxiety
    2019 PCB Conference: Strickland Benzodiazepines (BZDs), Herbal and Alternative Treatments for Anxiety & Depression BZD Learning Objectives • List at least three uses for benzodiazepines • Discuss at least two risk factors associated with benzodiazepine prescriptions Craig Strickland, PhD, Owner Biobehavioral Education and Consultation https://sites.google.com/site/bioedcon 1 2 BZD Pharmacokinetics Clinical Uses of BZDs Generic Name Trade Name Rapidity ½ Life Dose (mg) • Treat a variety of anxiety disorders alprazolam Xanax Intermediate Short 0.75-4 • Hypnotics • Muscle relaxants chlordiaze- Librium Intermediate Long 15-100 poxide • To produce anterograde amnesia clonazepam Klonopin Intermediate Long 0.5-4 • Alcohol & other CNS depressant withdrawal • Anti-convulsant therapy diazepam Valium Rapid Long 4-40 triazolam Halcion Intermediate Very short 0.125-0.5 temazepam Restoril Short Short 7.5-30 3 4 1 2019 PCB Conference: Strickland Issues with BZDs Herbal Medication and Alternative Therapies Used in the Treatment of Depression and Anxiety • Addictive potential • Confusion between “anti-anxiety” effects and the “warm-fuzzy) • Large dose ranges • Comparison of BZDs with medications like Buspar, etc. • They work, they work well and they work quickly 5 6 Alternative Tx. Learning Objectives Background Information on herbals: Natural does not necessarily mean “safe” • List several amino acid treatments for depression • Side-effects and adverse reactions • List at least three of the most common herbal – Herbal medications are “drugs” although
    [Show full text]
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Anti-Inflammatory Activity of Compounds from Kaempferia Marginata Rhizomes
    Songklanakarin J. Sci. Technol. 39 (1), 91-99, Jan. - Feb. 2017 http://www.sjst.psu.ac.th Original Article Anti-inflammatory activity of compounds from Kaempferia marginata rhizomes Kanidta Kaewkroek1, Chatchai Wattanapiromsakul1, 2, Hisashi Matsuda3, Seikou Nakamura3, and Supinya Tewtrakul1, 2* 1 Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, 90112 Thailand 2 Excellent Research Laboratory, Phytomedicine and Phamaceutical Biotechnology Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, 90112 Thailand 3 Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, 607-8412 Japan Received: 12 January 2016; Revised: 12 April 2016; Accepted: 19 April 2016 Abstract Two new pimarane diterpenes were obtained from Kaempferia marginata rhizomes, which are 1-acetoxysandara- copimaradien-2-one (1) and 1-acetoxysandaracopimaradiene (4), along with seven known compounds from the hexane and chloroform fractions including two pimarane-type diterpenes [marginatol (5), sandaracopimaradiene (8)], one kavalactone [desmethoxyyangonin (3)], three steroids [sitosterol--D-glucoside (2), the mixture of stigmasterol and -sitosterol (6 + 7)] and one diarylheptanoid [bisdemethoxycurcumin (9)]. Compounds 3 and 9 exhibited potent effect against NO production with IC50 of 10.1 and 6.8 µM, respectively. Compound 3 inhibited iNOS mRNA expression in a dose-dependent manner, while 9 suppressed both of iNOS and COX-2 genes. Moreover, compounds 2, 3, 6 + 7 and 9 were isolated for the first time from K. marginata. These results revealed that diterpenes, diarylheptanoid and kavalactone are components of K. marginata that afford anti-inflammatory effect through a mechanism involving a decrease in inflammatory mediators. Keywords: Kaempferia marginata, diterpenes, diarylheptanoid, kavalactone, anti-inflammatory activity 1.
    [Show full text]
  • Herbal Insomnia Medications That Target Gabaergic Systems: a Review of the Psychopharmacological Evidence
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2014, 12, 000-000 1 Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence Yuan Shia, Jing-Wen Donga, Jiang-He Zhaob, Li-Na Tanga and Jian-Jun Zhanga,* aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China; bDepartment of Pharmacology, School of Marine, Shandong University, Weihai, P.R. China Abstract: Insomnia is a common sleep disorder which is prevalent in women and the elderly. Current insomnia drugs mainly target the -aminobutyric acid (GABA) receptor, melatonin receptor, histamine receptor, orexin, and serotonin receptor. GABAA receptor modulators are ordinarily used to manage insomnia, but they are known to affect sleep maintenance, including residual effects, tolerance, and dependence. In an effort to discover new drugs that relieve insomnia symptoms while avoiding side effects, numerous studies focusing on the neurotransmitter GABA and herbal medicines have been conducted. Traditional herbal medicines, such as Piper methysticum and the seed of Zizyphus jujuba Mill var. spinosa, have been widely reported to improve sleep and other mental disorders. These herbal medicines have been applied for many years in folk medicine, and extracts of these medicines have been used to study their pharmacological actions and mechanisms. Although effective and relatively safe, natural plant products have some side effects, such as hepatotoxicity and skin reactions effects of Piper methysticum. In addition, there are insufficient evidences to certify the safety of most traditional herbal medicine. In this review, we provide an overview of the current state of knowledge regarding a variety of natural plant products that are commonly used to treat insomnia to facilitate future studies.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Diazepam and Kava Combination Article
    Journal of Advanced Research (2014) 5, 587–594 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Enhanced efficacy and reduced side effects of diazepam by kava combination Rasha A. Tawfiq a, Noha N. Nassar b,*, Wafaa I. El-Eraky c, Ezzeldein S. El-Denshary b a Egyptian Patent Office, Academy of Scientific Research and Technology, 101 Kasr El-Eini St., Cairo, Egypt b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Eini St., Cairo, Egypt c Department of Pharmacology, National Research Center, El-Tahrir St., Giza, Egypt ARTICLE INFO ABSTRACT Article history: The long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com- Received 2 April 2013 binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul- Received in revised form 18 July 2013 sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam Accepted 15 August 2013 (DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups Available online 22 August 2013 as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii) received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received Keywords: (iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/ Kava kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock Diazepam seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both Anticonvulsant acute and chronic treatment.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0311593 A1 Fischer Et Al
    US 20100311593A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0311593 A1 Fischer et al. (43) Pub. Date: Dec. 9, 2010 (54) HALOALKYLMETHYLENEOXYPHENYL- AOIPI3/00 (2006.01) SUBSTITUTED KETOENOLS C07D 207/00 (2006.01) C07D 305/12 (2006.01) (75) Inventors: Reiner Fischer, Monheim (DE): CD7C 49/00 (2006.01) Thomas Bretschneider, Lohmar C07D 23/00 (2006.01) (DE); Stefan Lehr, Liederbach C07C 229/00 (2006.01) (DE); Eva-Maria Franken, Lyon C07C 69/76 (2006.01) (FR): Olga Malsam, Rosrath (DE); CD7C 24I/00 (2006.01) Arnd Voerste, Koln (DE); Ulrich CD7C 63/04 (2006.01) Görgens, Ratingen (DE); Jan (52) U.S. Cl. ......... 504/219;564/170; 514/622:504/336; Dittgen, Frankfurt (DE); Dieter Feucht, Eschborn (DE); Isolde 504/236; 514/248; 544/235; 540/545; 514/211.08; Hauser-Hahn, Leverkusen (DE); 548/544; 549/319; 568/379: 548/366.4; 560/37; Christopher Hugh Rosinger, 560/76; 560/105:564/149; 562/493 Hofheim (DE); Alfred Angermann, Kriftel (DE) (57) ABSTRACT The invention relates to novel compounds of the formula (I), Correspondence Address: STERNE, KESSLER, GOLDSTEIN & FOX P.L. L.C. (I) 1100 NEW YORKAVENUE, N.W. WASHINGTON, DC 20005 (US) (73) Assignee: Bayer Cropscience AG, Monheim (DE) (21) Appl. No.: 12/639,536 (22) Filed: Mar. 11, 2010 in which W, X, Y, Z and CKE are each as defined above, to several methods and intermediates for preparation thereof (30) Foreign Application Priority Data and to the use thereofas pesticides and/or herbicides. The invention also relates to selective herbicidal composi Mar.
    [Show full text]
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Kava - the Unfolding Story: Report on a Work-In-Progress
    Article Kava - the unfolding story: Report on a work-in-progress. Denham, Alison, McIntyre, Michael and Whitehouse, Jule Available at http://clok.uclan.ac.uk/9455/ Denham, Alison, McIntyre, Michael and Whitehouse, Jule Kava - the unfolding story: Report on a work-in-progress. Journal of Alternative and Complementary Medicine, 8 (3). pp. 237-263. It is advisable to refer to the publisher’s version if you intend to cite from the work. For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>. For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the policies page. CLoK Central Lancashire online Knowledge www.clok.uclan.ac.uk THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 8, Number 3, 2002, pp. 237–263 © Mary Ann Liebert, Inc. SPECIAL REPORT Kava—the Unfolding Story: Report on a Work-in-Progress ALISON DENHAM, B.A. (Soc.), M.N.I.M.H., 1 MICHAEL McINTYRE, M.A., F.N.I.M.H., F.R.C.H.M., M.B.Ac.C., 2 and JULIE WHITEHOUSE, Ph.D., M.N.I.M.H. 3 ABSTRACT This paper, originated as a submission (now updated) to the U.K. Medicines Control Agency and Committee of Safety of Medicines (CSM) on January 11, 2002, in response to a report circu- lated by the German Federal Institute for Drugs and Medical Products (German initials are BfArM), a compilation of which is summarized in Appendix 2.
    [Show full text]